Nucleic acid-sensing Toll-like receptors (TLR3/7/8/9)

Nucleic acid-sensing Toll-like receptors (TLRs) are a specialized group of pattern recognition receptors located within the endosomal compartments of various immune cells, such as plasmacytoid dendritic cells and B cells. This group comprises Toll-like receptor 3, Toll-like receptor 7, Toll-like receptor 8, and Toll-like receptor 9, which are responsible for detecting double-stranded RNA, single-stranded RNA, and unmethylated CpG DNA, respectively (Kawai & Akira, 2011, Immunity). Upon activation by these nucleic acid ligands, the receptors trigger intracellular signaling pathways—primarily through the adapter proteins MyD88 or TRIF—that culminate in the expression of type I interferons and pro-inflammatory cytokines (Fitzgerald & Kagan, 2020, Cell). These receptors play a dual role in medicine: their agonists are employed as potent vaccine adjuvants and anti-tumor agents to stimulate the immune system against pathogens and malignancies (Kaczanowska et al., 2013, Gene Ther). Conversely, the inappropriate activation of these receptors by self-nucleic acids is a hallmark of autoimmune diseases like systemic lupus erythematosus and psoriasis, making them critical targets for antagonistic therapies (Lind et al., 2022, Nat Rev Immunol). Therapeutic development in this space focuses on balancing the potent immunostimulatory effects required for oncology with the need for precise inhibition in chronic inflammatory conditions.

Other names

Endosomal Toll-like receptorsNucleic acid-recognizing TLRsIntracellular Toll-like receptorsTLR3TLR7TLR8TLR9

Agonists bind to the endosomal domain of TLR3, TLR7, TLR8, or TLR9 to trigger MyD88- or TRIF-dependent signaling, leading to the activation of NF-κB and Interferon Regulatory Factors (IRFs). Antagonists competitively or non-competitively inhibit these receptors to prevent the recognition of endogenous or exogenous nucleic acids, thereby reducing inflammatory cytokine production.